# Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population

> **NCT00810316** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 24 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Alprazolam
- **DRUG:** Alprazolam XR
- **DRUG:** Clonazepam

## Key facts

- **NCT ID:** NCT00810316
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810316, "Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00810316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*